Featured Research Search Results

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

Surveys, Registries, Interviews
Study for people who have a BRCA1, BRCA2, or PALB2 genetic mutation

Study of the Drug Sovilnesib in People with Ovarian Cancer

Clinicaltrials.gov identifier:
NCT06084416

Treatment
Treatment study for people with platinum-resistant ovarian cancer

Screening Study for Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Clinicaltrials.gov identifier:
NCT05806515

Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation

Pancreatic Cancer Early Detection for People at High Risk

Clinicaltrials.gov identifier:
NCT04970056

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

Screening in Men at High Risk of Developing Prostate Cancer

Clinicaltrials.gov identifier:
NCT05608694

Prevention
Screening using MRI for men at risk of developing prostate cancer

A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)

Clinicaltrials.gov identifier:
NCT03729115

Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy

Clinicaltrials.gov identifier:
NCT05287451

Prevention
Prevention study for women at high risk for ovarian cancer

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Clinicaltrials.gov identifier:
NCT04550494

Treatment
Treatment study for people with advanced solid tumors

Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04858334

Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

Clinicaltrials.gov identifier:
NCT05129605

Prevention
People at high risk for prostate cancer due to an inherited mutation

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

Clinicaltrials.gov identifier:
NCT04038502

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

Blood Markers of Early Pancreas Cancer

Clinicaltrials.gov identifier:
NCT03568630

Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk

Bazedoxifene Plus Conjugated Estrogens for Hot Flashes in Women at High Risk for Breast Cancer

Clinicaltrials.gov identifier:
NCT04821141

Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes

BRCA 1 and BRCA 2: Interviews on Genetic Testing and Individual Experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing

Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells

Clinicaltrials.gov identifier:
NCT04150042

Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

Clinicaltrials.gov identifier:
NCT04548752

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation